

# Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma

NCT07218315

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	M.D. Anderson Cancer Center
Enrollment	15 participants

## Key Eligibility Criteria

---

### Inclusion (14)

- Participant must provide voluntary, written informed consent to participate in this clinical investigation.
- Participant agrees to comply with all study procedures, including all follow-up visits.
- Participant with a Bethesda VI cytology (tumor size  $\leq$  1.5 cm, no known regional/distant metastases)
- Participant with a Bethesda V cytology and normal calcitonin levels.
- Ultrasonographic evaluation of tumor to be ablated must show size of less than or equal to 1.5 cm and no extrathyroidal extension or locoregional metastases.
- ... and 9 more (see full listing online)

### Exclusion (5)

- FNA findings suggestive of high-grade malignancy
- Presence of regional or distant lymph node metastases.
- Participant had a history of previous neck irradiation.
- Females who are pregnant at time of enrollment.
- Participant has any condition or situation, in the opinion of the site Investigator, that puts the subject at significant risk, could confound the study results, or may interfere significantly with subject's participation in the study.

## Locations (2 total)

---

Sarasota Memorial Hospital, Sarasota, Florida, United States  
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States